Stocks to Watch: Kestrel Group, First Tracks Biotherapeutics, Inhibrx Biosciences

Dow Jones

May 09

By Kelly Cloonan

Kestrel Group recorded a wider loss in its latest quarter as expenses rose. The specialty insurance company's first-quarter loss was $7.4 million, or 96 cents a share, compared with a loss of $394,000, or 14 cents a share, a year earlier. The wider loss was driven by higher expenses, including an increase in general and administrative expenses. The stock fell 7.5% to $10.98 in late trading Friday.

First Tracks Biotherapeutics said existing stockholders would resell more than 10 million shares. The former subsidiary of AnaptysBio, which spun off in April, said shareholders would offload almost 10.5 million shares of common stock at prevailing market prices or in private deals. First Tracks won't receive any money from the sales. Shares were down 7.3% at $18.12 after hours.

Inhibrx Biosciences said it would release data from a Phase 2 study of INBRX-106, a potential cancer treatment, with plans to read out the data in a webcast at 8:30 a.m. EDT on Monday. INBRX-106 is being tested in combination with pembrolizumab to treat metastatic or unresectable recurrent head and neck squamous cell carcinoma. Shares rose 9.7% to $147.32 after the bell.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

May 08, 2026 18:40 ET (22:40 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2634498342"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2634498342\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2634498342?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-09 06:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2634498342","market":"hk","top_or_hot":-1,"title":"Stocks to Watch: Kestrel Group, First Tracks Biotherapeutics, Inhibrx Biosciences","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/KG\">Kestrel</a> Group recorded a wider loss in its latest quarter as expenses rose. The specialty insurance company's first-quarter loss was $7.4 million, or 96 cents a share, compared with a loss of $394,000, or 14 cents a share, a year earlier. The wider loss was driven by higher expenses, including an increase in general and administrative expenses. The stock fell 7.5% to $10.98 in late trading Friday. \n</p>\n<p>\n  First Tracks Biotherapeutics said existing stockholders would resell more than 10 million shares. The former subsidiary of AnaptysBio, which spun off in April, said shareholders would offload almost 10.5 million shares of common stock at prevailing market prices or in private deals. First Tracks won't receive any money from the sales. Shares were down 7.3% at $18.12 after hours. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/INBX\">Inhibrx Biosciences</a> said it would release data from a Phase 2 study of INBRX-106, a potential cancer treatment, with plans to read out the data in a webcast at 8:30 a.m. EDT on Monday. INBRX-106 is being tested in combination with pembrolizumab to treat metastatic or unresectable recurrent head and neck squamous cell carcinoma. Shares rose 9.7% to $147.32 after the bell. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 08, 2026 18:40 ET (22:40 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks to Watch: Kestrel Group, First Tracks Biotherapeutics, Inhibrx Biosciences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks to Watch: Kestrel Group, First Tracks Biotherapeutics, Inhibrx Biosciences\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-09 06:40</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/KG\">Kestrel</a> Group recorded a wider loss in its latest quarter as expenses rose. The specialty insurance company's first-quarter loss was $7.4 million, or 96 cents a share, compared with a loss of $394,000, or 14 cents a share, a year earlier. The wider loss was driven by higher expenses, including an increase in general and administrative expenses. The stock fell 7.5% to $10.98 in late trading Friday. \n</p>\n<p>\n  First Tracks Biotherapeutics said existing stockholders would resell more than 10 million shares. The former subsidiary of AnaptysBio, which spun off in April, said shareholders would offload almost 10.5 million shares of common stock at prevailing market prices or in private deals. First Tracks won't receive any money from the sales. Shares were down 7.3% at $18.12 after hours. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/INBX\">Inhibrx Biosciences</a> said it would release data from a Phase 2 study of INBRX-106, a potential cancer treatment, with plans to read out the data in a webcast at 8:30 a.m. EDT on Monday. INBRX-106 is being tested in combination with pembrolizumab to treat metastatic or unresectable recurrent head and neck squamous cell carcinoma. Shares rose 9.7% to $147.32 after the bell. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 08, 2026 18:40 ET (22:40 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2634498342","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2634498342","pubTimestamp":1778280000,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Kestrel Group recorded a wider loss in its latest quarter as expenses rose. The specialty insurance company's first-quarter loss was $7.4 million, or 96 cents a share, compared with a loss of $394,000, or 14 cents a share, a year earlier. The wider loss was driven by higher expenses, including an increase in general and administrative expenses. The stock fell 7.5% to $10.98 in late trading Friday.First Tracks Biotherapeutics said existing stockholders would resell more than 10 million shares. The former subsidiary of AnaptysBio, which spun off in April, said shareholders would offload almost 10.5 million shares of common stock at prevailing market prices or in private deals. First Tracks won't receive any money from the sales. Shares were down 7.3% at $18.12 after hours.Inhibrx Biosciences said it would release data from a Phase 2 study of INBRX-106, a potential cancer treatment, with plans to read out the data in a webcast at 8:30 a.m. EDT on Monday. INBRX-106 is being tested in combi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","KG":"Kestrel","INBX":"Inhibrx Biosciences","BK4019":"再保险"},"translate_title":"值得关注的股票：Kestrel Group、First Tracks Biotherapeutics、Inhibrx Biosciences","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KG":1.5,"INBX":1.5},"content_text":"By Kelly Cloonan \n\n\n \n\n\nKestrel Group recorded a wider loss in its latest quarter as expenses rose. The specialty insurance company's first-quarter loss was $7.4 million, or 96 cents a share, compared with a loss of $394,000, or 14 cents a share, a year earlier. The wider loss was driven by higher expenses, including an increase in general and administrative expenses. The stock fell 7.5% to $10.98 in late trading Friday. \n\n\n  First Tracks Biotherapeutics said existing stockholders would resell more than 10 million shares. The former subsidiary of AnaptysBio, which spun off in April, said shareholders would offload almost 10.5 million shares of common stock at prevailing market prices or in private deals. First Tracks won't receive any money from the sales. Shares were down 7.3% at $18.12 after hours. \n\n\nInhibrx Biosciences said it would release data from a Phase 2 study of INBRX-106, a potential cancer treatment, with plans to read out the data in a webcast at 8:30 a.m. EDT on Monday. INBRX-106 is being tested in combination with pembrolizumab to treat metastatic or unresectable recurrent head and neck squamous cell carcinoma. Shares rose 9.7% to $147.32 after the bell. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 08, 2026 18:40 ET (22:40 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}